Unicycive(UNCY) - 2025 Q3 - Quarterly Results

Financial Position - As of September 30, 2025, Unicycive Therapeutics expects to report approximately $42 million in cash and cash equivalents[6] Regulatory Updates - The company received a Complete Response Letter from the U.S. FDA on June 30, 2025, regarding its New Drug Application for Oxylanthanum Carbonate[8] - An update on the timing of the resubmission of the New Drug Application was announced on October 28, 2025[8]